Related references
Note: Only part of the references are listed.Effects of Deacetylase Inhibition on the Activation of the Antioxidant Response and Aerobic Metabolism in Cellular Models of Fanconi Anemia
Nadia Bertola et al.
ANTIOXIDANTS (2023)
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance
Michele Zanoni et al.
FRONTIERS IN MEDICINE (2022)
Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin
Avital Granit et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism
Hanxun Yue et al.
FRONTIERS IN ONCOLOGY (2022)
Cisplatin for cancer therapy and overcoming chemoresistance
Ranmali Ranasinghe et al.
HELIYON (2022)
ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression
Cuicui Liu et al.
CANCER RESEARCH (2021)
Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform
Bo Pan et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2021)
Valproic Acid and Breast Cancer: State of the Art in 2021
Anna Wawruszak et al.
CANCERS (2021)
ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin
Wei Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The prognostic significance of ALDH1A1 expression in early invasive breast cancer
Maryam Althobiti et al.
HISTOPATHOLOGY (2020)
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra et al.
NPJ BREAST CANCER (2020)
Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer
Michael Dunne et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma
Xinwei Yun et al.
MOLECULAR CANCER RESEARCH (2018)
Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism
Wangie Yu et al.
SCIENTIFIC REPORTS (2018)
Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells
Alysha K. Croker et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer
Xiaoling Qian et al.
ONCOTARGET (2017)
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
Kyung-Min Lee et al.
CELL METABOLISM (2017)
Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
Nathan J. Lanning et al.
CANCER & METABOLISM (2017)
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yuhki Yokoyama et al.
CANCER RESEARCH (2016)
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism
Bisrat G. Debeb et al.
ONCOTARGET (2016)
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer
Mehmet Asim Bilen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Hovav Nechushtan et al.
ONCOLOGIST (2015)
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis
Anna Wawruszak et al.
PLOS ONE (2015)
Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma
Tri Budi Hartomo et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin
G. Dominguez-Gomez et al.
ONCOLOGY REPORTS (2015)
Aldehyde dehydrogenases in cancer: an opporunity for biomaker and drug development?
Klaus Pors et al.
DRUG DISCOVERY TODAY (2014)
被撤回的出版物: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (Retracted article. See vol. 119, 2022)
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress
Surendra Singh et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Rossella Marullo et al.
PLOS ONE (2013)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β-Catenin Signaling
Bisrat G. Debeb et al.
STEM CELLS (2012)
Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application
Vindhya Koppaka et al.
PHARMACOLOGICAL REVIEWS (2012)
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression
Koji Morimoto et al.
CANCER SCIENCE (2009)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
Brian D. Lawenda et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2007)
Tumor-specific positron emission tomography Imaging in patients:: [18F) fluorodeoxyglucose and beyond
David A. Mankoff et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
